Is Baxter's Sell-off an Opportunity for Long-Term Investors?

Baxter International Inc. (NYSE:BAX) is one of the most undervalued and overlooked large-cap stocks. On August 4, a Barclays analyst lowered his price target on Baxter International Inc. (NYSE:BAX) to $36 from $41, while maintaining an Overweight rating. The cut followed a sharp 24% decline in the stock after Q2 results, driven by the pause of its Novum pump program and reduced 2025 outlook.

The analyst argued that the sell-off was “significantly overdone” and sees current levels as an attractive entry point. Despite mixed Q2 results, Baxter International Inc. (NYSE:BAX) still expects 2025 operational sales growth of 3%-4%, down from 4%-5%, with EPS guidance narrowed to $2.42-$2.52 from $2.47-$2.55.

The analyst believes that investor concerns about pump delays and execution risks are overly discounted in the stock price. This, according to him, creates an opportunity for value-oriented investors willing to look past near-term uncertainty.

Baxter International Inc. (NYSE:BAX) is a healthcare company offering products in infusion systems, renal therapies, and surgical equipment, serving hospitals and clinics worldwide.

While we acknowledge the potential of BAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Stocks to Buy and Hold Forever and 12 Overlooked Large-Cap Stocks with Low Multiples.

Disclosure: None. This article is originally published at Insider Monkey.